01—Abstract
Summary
Summary of the 10-Q filed November 3, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. reported third-quarter 2025 total revenues of $354.3 milliona, up from $290.1 million a year earlier, with net income of $175.2 million (diluted EPS $1.43, versus $1.05).
Royalties were $236.0 millionb, up from $155.1 million, driven mainly by VYVGART Hytrulo, DARZALEX SC and Phesgo. For the nine months, total revenues were $944.8 million and net income was $458.5 million, with net cash provided by operating activities of $432.5 million. Cash, cash equivalents and marketable securities totaled $702.0 million at September 30, 2025, and management states these are sufficient to fund operations for at least the next 12 months.
The company repurchased $342.4 millionc of common stock in the nine months under its $750.0 million program, with $92.3 million used in the third tranche as of quarter-end. The 2028 Convertible Notes ($720.0 million principal) were reclassified to current debt because their conditional conversion feature was triggered, and total current liabilities rose to $837.2 million.
The filing states that the company agreed in September 2025 to acquire Elektrofi, Inc. for $750 milliond upfront plus up to three $50 million milestone payments, with closing expected in the fourth quarter of 2025 subject to antitrust review. The company also filed a patent infringement lawsuit against Merck in April 2025 concerning its MDASE technology, and notes that Otter discontinued marketing OTREXUP in August 2025.
02—Key points
Key Highlights
- Total revenues of $354.3 million for Q3 2025, up from $290.1 million; nine-month revenues of $944.8 million versus $717.3 million
- Royalties rose to $236.0 million in Q3 from $155.1 million, led by VYVGART Hytrulo, DARZALEX SC and Phesgo
- Net income of $175.2 million in Q3 (diluted EPS $1.43) versus $137.0 million (diluted EPS $1.05) a year earlier
- Cash, cash equivalents and marketable securities of $702.0 million at September 30, 2025; management believes this is sufficient for at least 12 months
- $342.4 million spent on share repurchases in the first nine months of 2025 under the $750.0 million program
- The 2028 Convertible Notes were classified as current debt after their conditional conversion feature was triggered, lifting current liabilities to $837.2 million
- Agreed to acquire Elektrofi, Inc. for $750 million upfront plus up to three $50 million milestones, with closing expected in Q4 2025
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Halozyme Therapeutics kept $0.49.
- Revenue$354.3M100.0%
- Cost of revenue−$55.2M15.6%
- Gross profit$299.0M84.4%
- Operating costs−$81.1M22.9%
- Operating income$217.9M61.5%
- Interest, other & tax−$42.7M12.1%
- Net income$175.2M49.5%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed November 3, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $354.26M$290.08M | +22.1% |
| Cost of Revenue | $55.24M$49.43M | +11.8% |
| Gross Profit | $299.02M$240.66M | +24.3% |
| R&D Expenses | $17.25M$18.46M | −6.5% |
| SG&A Expenses | $46.09M$41.24M | +11.8% |
| Operating Expenses | $136.34M$126.89M | +7.5% |
| Operating Income | $217.92M$163.20M | +33.5% |
| Net Income | $175.22M$137.01M | +27.9% |
| EPS (Basic) | $1.49$1.08 | +38.0% |
| EPS (Diluted) | $1.43$1.05 | +36.2% |
| Shares Outstanding (Basic) | 117.22M126.85M | −7.6% |
| Shares Outstanding (Diluted) | 122.33M130.13M | −6.0% |
05—Questions
Frequently Asked Questions
What drove the growth in Halozyme's royalty revenue this quarter?
The filing attributes the increase primarily to continued sales uptake of ENHANZE partner products launched since 2020, predominantly VYVGART Hytrulo by argenx, DARZALEX SC by Janssen and Phesgo by Roche. Those three products contributed approximately $71.2 million to the year-over-year increase in Q3 royalties, partly offset by price erosion on earlier-launched products such as Herceptin and MabThera.
Does the company have enough liquidity to meet its obligations?
Management states that existing cash, cash equivalents and marketable securities of $702.0 million will be sufficient to fund operations for at least the next 12 months. The $750 million Elektrofi acquisition is described as subject to closing conditions, and the 2027 and 2028 Convertible Notes carry principal of $805.0 million and $720.0 million, respectively. The $575 million revolving credit facility was undrawn at September 30, 2025.
Why did the convertible debt move into current liabilities?
As of September 30, 2025, the conditional conversion feature of the 2028 Convertible Notes was triggered, so the notes were classified as current portion of long-term debt, net, at a carrying amount of $710.7 million. The filing states the company was in compliance with all covenants.
What is the Elektrofi acquisition and what does it cost?
In September 2025, Halozyme agreed to acquire Elektrofi, Inc., a biopharmaceutical company with ultra-high concentration microparticle technology for biologics branded Hypercon. The consideration is $750 million in upfront payment plus up to three $50 million milestone payments tied to separate product regulatory approvals. Closing is expected in the fourth quarter of 2025, subject to antitrust review and other customary conditions.
How much did the company return to shareholders this period?
In the nine months ended September 30, 2025, the cash flow statement shows $342.4 million of common stock repurchases. Under the February 2024 $750.0 million program, the company repurchased 6,996,305 shares for a total cost of $366.8 million across 2025 quarters, with $157.6 million of authorization remaining as of September 30, 2025.
06—Continue